Rimas V. Lukas
Experienced in Synovial Sarcoma

Dr. Rimas V. Lukas

Hematology Oncology | Neurology | Hematology
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
23 Years of Experience
Experienced in Synovial Sarcoma
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rimas Lukas is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Lukas has been practicing medicine for over 23 years and is rated as an Experienced provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, Brain Tumor, and Gastrostomy.

His clinical research consists of co-authoring 194 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Rush University Medical College, 2002
Residency
University of Chicago
Specialties
Hematology Oncology
Neurology
Hematology
Licenses
Psychiatry & Neurology in IL
Board Certifications
American Board Of Psychiatry And Neurology - Neurology (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Medicine Mchenry
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

675 N St Clair St Ste 20-100, Galter Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Lukas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma
Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Drug, Device
Study Drug: Chemotherapy, Albumin-Bound Paclitaxel
Study Phase: Phase 1/Phase 2
Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Drug, Radiation
Study Drugs: BMS-986205, Nivolumab, Temozolomide
Study Phase: Phase 1
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Enrollment Status: Terminated
Publish Date: June 06, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Memantine
Study Phase: Phase 3
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug, Biological
Study Drugs: Ad-RTS-hIL-12, Veledimex
Study Phase: Phase 1
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

194 Total Publications

Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.
Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.
Journal: Research square
Published: October 03, 2025
Similar Doctors
Distinguished in Synovial Sarcoma
Dr. Marta Batus
Oncology
Distinguished in Synovial Sarcoma
Dr. Marta Batus
Oncology

Rush University Medical Group

1620 W Harrison St, 
Chicago, IL 
 (3.2 miles away)
Languages Spoken:
English, Polish, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Marta Batus is an Oncologist in Chicago, Illinois. Dr. Batus is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Adult Soft Tissue Sarcoma, and Small Cell Lung Cancer (SCLC). Dr. Batus is currently accepting new patients.

Distinguished in Synovial Sarcoma
Dr. Pedro A. Hermida-De
Hematology | Oncology
Distinguished in Synovial Sarcoma
Dr. Pedro A. Hermida-De
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pedro Hermida-De is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Hermida-De is rated as a Distinguished provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Bone Tumor, Synovial Sarcoma, Rhabdoid Tumor, Rhabdoid Tumor Predisposition Syndrome, and Gamma Knife Radiosurgery. Dr. Hermida-De is currently accepting new patients.

Distinguished in Synovial Sarcoma
Dr. Samir D. Undevia
Hematology | Oncology
Distinguished in Synovial Sarcoma
Dr. Samir D. Undevia
Hematology | Oncology

Endeavor Health Medical Group

801 S Washington St, Fl 3, 
Naperville, IL 
 (29.4 miles away)
630-527-5359
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Samir Undevia is a Hematologist and an Oncologist in Naperville, Illinois. Dr. Undevia is rated as a Distinguished provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Epithelioid Sarcoma, and Myxoid Liposarcoma. Dr. Undevia is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lukas's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 20 Advanced Conditions
View All 83 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile